INDERIDE LA 120/50 Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Inderide La 120/50, and when can generic versions of Inderide La 120/50 launch?
Inderide La 120/50 is a drug marketed by Wyeth Ayerst and is included in one NDA.
The generic ingredient in INDERIDE LA 120/50 is hydrochlorothiazide; propranolol hydrochloride. There are thirty-two drug master file entries for this compound. Additional details are available on the hydrochlorothiazide; propranolol hydrochloride profile page.
Summary for INDERIDE LA 120/50
US Patents: | 0 |
Applicants: | 1 |
NDAs: | 1 |
Raw Ingredient (Bulk) Api Vendors: | 1 |
Formulation / Manufacturing: | see details |
DailyMed Link: | INDERIDE LA 120/50 at DailyMed |
Anatomical Therapeutic Chemical (ATC) Classes for INDERIDE LA 120/50
US Patents and Regulatory Information for INDERIDE LA 120/50
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Wyeth Ayerst | INDERIDE LA 120/50 | hydrochlorothiazide; propranolol hydrochloride | CAPSULE, EXTENDED RELEASE;ORAL | 019059-002 | Jul 3, 1985 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for INDERIDE LA 120/50
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Wyeth Ayerst | INDERIDE LA 120/50 | hydrochlorothiazide; propranolol hydrochloride | CAPSULE, EXTENDED RELEASE;ORAL | 019059-002 | Jul 3, 1985 | ⤷ Try a Trial | ⤷ Try a Trial |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for INDERIDE LA 120/50
See the table below for patents covering INDERIDE LA 120/50 around the world.
Country | Patent Number | Title | Estimated Expiration |
---|---|---|---|
Hong Kong | 10381 | SUSTAINED RELEASE PHARMACEUTICAL COMPOSTION | ⤷ Try a Trial |
Japan | S5740804 | ⤷ Try a Trial | |
France | 2392667 | ⤷ Try a Trial | |
New Zealand | 185101 | SUSTAINED RELEASE PHARMACEUTICAL COMPOSITIONS CONTAINING PROPRANOLOL | ⤷ Try a Trial |
>Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for INDERIDE LA 120/50
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
0443983 | C00443983/03 | Switzerland | ⤷ Try a Trial | PRODUCT NAME: VALSARTAN + AMLODIPINE + HYDROCHLOROTHIAZIDE; REGISTRATION NUMBER/DATE: SWISSMEDIC 59407 16.09.2009 |
0565634 | 06C0030 | France | ⤷ Try a Trial | PRODUCT NAME: EPROSARTAN MESYLATE; HYDROCHLOROTHIAZIDE; NAT. REGISTRATION NO/DATE: NL 32075 20060623; FIRST REGISTRATION: LI - 55783 01 20020607 |
0454511 | 99C0009 | Belgium | ⤷ Try a Trial | PRODUCT NAME: IRBESARTAN / HYDROCHLOROTHIAZIDE; REGISTRATION NO/DATE: EU/1/98/086/001 19981015 |
0503785 | CA 2011 00026 | Denmark | ⤷ Try a Trial | PRODUCT NAME: A COMBINATION OF OLMESARTAN MEDOXOMIL, OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT, AND AMLODIPINE BESYLATE AND HYDROCHLOROTHIAZIDE; NAT. REG. NO/DATE: 46260-46269 (DK) 20110323; FIRST REG. NO/DATE: DE 79810.00.00 20101216 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |